Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Pfizer partner BioNTech starts cancer vaccine phase 2 trial

<< Previous

Bullboard Posts

Next >>

Comment by Rumpl3StiltSkinon Jun 23, 2021 6:02pm

216 Views

Post# 33438752

RE:RE:RE:RE:RE:RE:RE:Pfizer partner BioNTech starts cancer vaccine phase 2 trial

Eoganacht wrote: Hi Rumpl3StiltSkin. I think the 2 vaccines would be quite different. The anti-cancer vaccine would be created from the products of cancer cells treated outside the body with Theralase's pdt and the anti-pathogen vaccine would be created from the products created by treating Covid-19 outside the body with Theralase's pdt.

Rumpl3StiltSkin wrote:

Thanks Eoga,

For the sanity check. You've been staying on top of this stuff much better than I. For some reason(s) I've been thinking the MoA of Ruvacare might be similar enough to cover both Covid and Cancer in the safety studies. So that perhaps Phase 1s could be eliminated for the cancer indications. But that would be a best case and perhaps a stretch...

Got ya,

I think the key is even though they are both using 1433/Rutherrin or Ruvacare? that they are doing it outside the body with completely different diseases. So how would they then react when introduced back into the body? And both vaccines would then be different than the GLP animal studies they are doing now...Which will probably be fine to set up cancer treatment phase 1s for different indications. The Vaccine part of this ACT is handled a bit differently then it seems?

<< Previous

Bullboard Posts

Next >>

POET increases production capacity to meet AI demand